ImPassion130 Study Outcomes

obr has 860 videos Subscribe Here

Description: Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Women’s Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School shares the results of ImPassion130 study, a phase III adding atezolizumab to the 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative cancer (TNBC).
Shared By : obr
Posted on : 07/02/19
Added : 17 days ago
Category : Breast Cancer